Polymer-free drug-eluting stents showed comparable clinical outcomes to modern permanent- or biodegradable polymer-based DES up to 5 years after implantation.
Do polymer-free drug-eluting stents improve clinical outcomes compared to polymer-based DES in patients with coronary artery disease?
Polymer-free drug-eluting stents provide comparable clinical outcomes to modern polymer-based DES up to 5 years, serving as a viable option for percutaneous treatment of coronary artery disease.
Polymer-free drug-eluting stents (PF-DES) were designed with the expectation of avoiding late restenosis and thrombosis related to the polymer used in traditional DES platforms. Furthermore, due to similarities with bare metal stents after drug elution, PF-DES has been considered as particularly suitable for patients at high bleeding risk. A variety of PF-DES platforms have been clinically tested. Despite their theoretical advantages, PF platforms showed comparable clinical outcomes with modern permanent- or biodegradable polymer-based DES up to 5 years after implantation. Use of more biocompatible polymers on the modern DES platforms is one of the reasons therefore. Their improved safety profile allows already less intensive antithrombotic regimes after DES. Hence, nowadays PF-DES platforms can be considered as one of many DES options for percutaneous treatment of coronary artery disease.
Baquet et al. (Tue,) conducted a review in Coronary artery disease. Polymer-free drug-eluting stents (PF-DES) vs. Modern permanent- or biodegradable polymer-based DES was evaluated on Clinical outcomes. Polymer-free drug-eluting stents showed comparable clinical outcomes to modern permanent- or biodegradable polymer-based DES up to 5 years after implantation.